Therapeutic options for postmenopausal female sexual dysfunction

Al‐Azzawi, Farook; Bitzer, Johannes; Brandenburg, Ulrike; Castelo-Branco, Camil; Graziottin, Alessandra; Kenemans, P.; Lachowsky, M.; Mimoun, S.; Nappi, Rossella E.; Palacios, Santiago; Schwenkhagen, A.; Studd, John; Wylie, Kevan; Zahradnik, H. P.

doi:10.3109/13697130903437615

Cited by 67 publications

(58 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…103 However, when estrogens are used, the risks of such therapy should be taken into consideration, while careful choice of the most appropriate agent and route of administration are of major importance. 95,103,104 Importantly, in women with diabetes the effects of estrogens on lipid profile should be taken seriously into account. 105 Studies have established the role of testosterone in female sexual desire, arousal, genital sensation, and orgasm.…”

Section: Therapeutic Approach To Sexual Dysfunction In Women With Diamentioning

confidence: 99%

“…Furthermore, lifestyle changes such as implementation of a healthy and balanced diet, regular exercise, and body weight control are suggested not only for achieving better glucose levels but because they have been found to improve female sexual function. 95 Pharmacological treatment for FSD is also available and current treatment options are based on hormonal therapies and agents that act either centrally or peripherally. However, further research is needed in this domain for design of improved treatments.…”

Section: Therapeutic Approach To Sexual Dysfunction In Women With Diamentioning

confidence: 99%

“…Cognitive-behavioral psychotherapy is the proposed treatment for women suffering from desire disorders or vaginismus, while couple therapy has been proven to result in greater partner intimacy. 37,95 Women with arousal or orgasm disorders can benefit from the FDA approved Eros clitoral therapy device. 37,[96][97][98][99][100] The device is placed over the clitoris and creates a gentle vacuum that increases the genital blood flow, enhancing the genital sensitivity.…”

Section: Therapeutic Approach To Sexual Dysfunction In Women With Diamentioning

confidence: 99%

See 2 more Smart Citations

Sexual dysfunction in diabetic women

Bargiota¹,

Dimitropoulos²,

Tzortzis³

et al. 2011

View full text Add to dashboard Cite

Section: Therapeutic Approach To Sexual Dysfunction In Women With Diamentioning

confidence: 99%

Section: Therapeutic Approach To Sexual Dysfunction In Women With Diamentioning

confidence: 99%

Section: Therapeutic Approach To Sexual Dysfunction In Women With Diamentioning

confidence: 99%

See 1 more Smart Citation

Sexual dysfunction in diabetic women

Bargiota¹,

Dimitropoulos²,

Tzortzis³

et al. 2011

View full text Add to dashboard Cite

“…Jakkolwiek brakuje dużych, wiarygodnych badań oceniających wpływ hormonalnej terapii zastępczej (HTZ) na przebieg SM, istnieją pojedyncze doniesienia wskazujące na poprawę stanu chorych stosujących HTZ [42]. Pozytywny wpływ HTZ na funkcje seksualne u kobiet w wieku menopauzalnym jest natomiast dobrze udokumentowany [43][44][45].…”

Section: Aspekty Związane Z Ciążą Menopauzą I Terapią Hormonalnąunclassified

Therapy of female sexual dysfunction in multiple sclerosis

Lew–Starowicz¹,

Rola²

2013

View full text Add to dashboard Cite

166 StreszczenieStwardnienie rozsiane (sclerosis multiplex -SM) jest jedną z najbardziej powszechnych chorób neurologicznych. Dotyka dwukrotnie częściej kobiety niż mężczyzn i przyczynia się do występowania dysfunkcji seksualnych o złożonej etiologii, które wywierają negatywny wpływ na jakość życia chorych oraz ich relacje w związkach partnerskich. Problemy seksualne u kobiet z SM pozostają niestety często nierozpoznane i nieleczone. Autorzy przedstawiają aktualny stan wiedzy i proponują algorytm terapeutyczny dostosowany do leczenia dysfunkcji seksualnych u kobiet z SM.Słowa kluczowe: stwardnienie rozsiane, dysfunkcje seksualne kobiet, terapia. SummaryMultiple sclerosis (MS) is one of the most prevalent neurological diseases. It is twice as frequent in women as in men. It contributes to sexual dysfunctions that have complex etiology and negative impact on patients' quality of life as well as their relationships. Unfortunately, sexual concerns in MS women often remain unrecognized and untreated. The authors present the current state of knowledge and propose a therapeutical algorithm for the treatment of MS female sexual dysfunction.

show abstract

“…Общая оценка шкалы FSFI равна сумме баллов по 6 доменам, причем более высокие баллы отражают лучшую сексуальную функцию (диапазон общей оценки FSFI 0-36). Общий балл FSFI менее 26,55 определялся как низкая сексуальная функция (LSF) [42][43][44]. В KEEPS t-E2 непосредственно сопоставлялся с перораль-ным конъюгированным конским эстрогеном (o-CEE) для определения, оказывают ли они эквивалентное влияние на симптомы, связанные с менопаузой [45].…”

unclassified

The effectiveness and safety of mht depending on the type, route of administration of estrogens, and the type of progestogen. Analysis of data from clinical trials and international recommendations

Шурпяк

2017

View full text Add to dashboard Cite

The hormone therapy remains the most effective method for treating of the vasomotor symptoms and genitourinary syndrome in menopause. The evidence available to date suggests that for women younger than 60 and with a postmenopause no more than 10 years without contraindications, the benefits of administering systemic hormone therapy for the treatment of vasomotor symptoms, sleep disorders and prevention of bone loss exceed possible risks. In addition, the data about statistically significant reduction in all-cause mortality in women who initiate hormone therapy before the age of 60 and/or 10 years after the onset of menopause have been obtained.Menopausal hormone therapy (MHT) includes a wide range of hormonal drugs and administration routes that potentially have different risks and benefits, and therefore the term “class effect” is misleading and inappropriate. The risks of menopausal hormone therapy vary depending on the composition, dose and route of administration of hormones, as well as the timing of the onset and duration of use of both estrogens and progesterone. The use of transdermal estrogens in combination with progesterone seems safer for venous thromboembolism, especially in high-risk women. The use of transdermal estrogen drugs in comparison with oral estrogens is associated with a lesser likelihood of developing thrombotic risk, and possibly the risk of developing stroke and coronary heart disease. If progesterone is needed, micronized progesterone is a safer alternative.MHT requires a periodic reassessment of the benefits and risks for deciding whether to continue or stop using it. The use of postmenopausal hormone therapy in women with menopausal disorders should be based on an assessment of all risk factors for cardiovascular disease, age and time from the onset of menopause. The duration of therapy should be motivated by the indications, and the decision should be taken in conjunction with the doctor.

show abstract

Therapeutic options for postmenopausal female sexual dysfunction

Cited by 67 publications

References 61 publications

Sexual dysfunction in diabetic women

Sexual dysfunction in diabetic women

Therapy of female sexual dysfunction in multiple sclerosis

The effectiveness and safety of mht depending on the type, route of administration of estrogens, and the type of progestogen. Analysis of data from clinical trials and international recommendations

Contact Info

Product

Resources

About